Safety and Pharmacokinetics of Subcutaneous Injection of OCTA101 in Adult Patients With Severe Hemophilia A

PHASE1/PHASE2TerminatedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 3, 2019

Primary Completion Date

February 18, 2022

Study Completion Date

February 18, 2022

Conditions

Severe Hemophilia A

Interventions

DRUG

OCTA101

OCTA101 is composed of OCTA8 (human-cl rhFVIII - Nuwiq Intermediate 2 Q-Eluate) and OCTA12 (recombinant human VWF fragment dimer).

Trial Locations (1)

Specialized Hospital for Active Treatment of Hematological Diseases EAD Clinic of Clinical Hematology, Sofia